Literature DB >> 12918460

Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma.

Tito Livraghi1.   

Abstract

At detection or over time, hepatocellular carcinoma(HCC) is multicentric in origin, against a background of chronic hepatic disease at different stages. Orthotopic liver transplantation (OLT) is the only therapy able to definitely cure both diseases. When OLT is not feasible, all other options can be only palliative. Owing to the multicentricity, surgical resection may be one possible option at the initial detection in selected patients, whereas percutaneous interventional techniques (percutaneous ethanol injection [PEI], radiofrequency ablation [RFA], selected transcatheter arterial chemoembolization [TACE]) are the options more of tenused. The range of their indications is becoming wider. Although it is understood that partial resection assures the greatest local control, the survival rates after surgery are roughly comparable with those obtained with PEI. The explanation for this result reflects a balance among the advantages and disadvantages of the two therapies. PEI survival curves are better than curves of resected patients who present with adverse prognostic factors, and this means that a better selection of the patients for surgery is needed. An open question remains the choice among percutaneous techniques. In our department we currently use RFA in most patients but consider PEI and selected TACE complementary, and use them according to the features of the disease and the response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918460     DOI: 10.1007/s10534-002-0714-y

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  21 in total

1.  Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation?

Authors:  Jung Hyeok Kwon
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

2.  [Liver tumor ablation].

Authors:  Th Helmberger; R-Th Hoffmann; T Jakobs; Th Leibecke; A Lubienski; M Reiser
Journal:  Radiologe       Date:  2005-01       Impact factor: 0.635

3.  A tamponade leading to death after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Ahmed Moumouh; Jérôme Hannequin; Carine Chagneau; Fatima Rayeh; Arnaud Jeanny; Alexandre Weber-Holtzscherer; Jean-Pierre Tasu
Journal:  Eur Radiol       Date:  2004-10-16       Impact factor: 5.315

4.  Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications.

Authors:  Min-Hua Chen; Wei Yang; Kun Yan; Wen Gao; Ying Dai; Yan-Bin Wang; Xiao-Peng Zhang; Shan-Shan Yin
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C.

Authors:  Yutaka Yamanaka; Katsuya Shiraki; Kazumi Miyashita; Tomoko Inoue; Tomoyuki Kawakita; Yumi Yamaguchi; Yukiko Saitou; Norihiko Yamamoto; Takeshi Nakano; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

6.  Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT).

Authors:  Stephan Zangos; Katrin Eichler; Jörn O Balzer; Ralf Straub; Renate Hammerstingl; Christopher Herzog; Thomas Lehnert; Mathias Heller; Axel Thalhammer; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-08-08       Impact factor: 5.315

7.  High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma.

Authors:  Tao Li; Yuhua Zhu; Wanhua Ren; Shifeng Xu; Zhen Yang; Aiju Fang; Chengyong Qin
Journal:  Med Oncol       Date:  2012-01-15       Impact factor: 3.064

8.  A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes.

Authors:  Jean C Emond; Benjamin Samstein; John F Renz
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

9.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma.

Authors:  Tatsuya Higashi; Etsuro Hatano; Iwao Ikai; Ryuichi Nishii; Yuji Nakamoto; Koichi Ishizu; Tsuyoshi Suga; Hidekazu Kawashima; Kaori Togashi; Satoru Seo; Koji Kitamura; Yasutsugu Takada; Yasuji Takada; Shinji Uemoto; Shinji Kamimoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.